Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF)
Combined double immune checkpoint inhibition and radiofrequency electromagnetic field treatment for patients with advanced hepatocellular carcinoma
Trial Details
- NCT ID
- NCT06821958
- Phase
- NA
- Sponsor
- Charite University, Berlin, Germany
- Status
- RECRUITING
- Cancer Type
- Liver Cancer
- Interventions
- Radiofrequency electromagnetic field treatment
- Locations (sample)
- Berlin, Germany|52.52437,13.41053
Key Eligibility Criteria
- Treatment with combined Anti-PD-L1 and Anti-CTLA-4 antibodies
- Written informed consent prior to any study procedure
- 18 years or older
- Histologically confirmed HCC
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Liver Cancer Trials on Trialify →